Clinical trials: Cohort
Macular Degeneration
Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration
The study will provide additional safety data for specific safety events in persons receiving intravitreal injections. The Committee for Medicinal Products for Human Use (CHMP) is interested in obtaining additional safety…
- Trial name
- NCT00460408
- Testing
- Macugen
- Where
- 68 sites in Belgium, Cyprus and 11 more
- Volunteers
- 501 people
- Sponsor
- Pfizer
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)
The purpose of this study is to determine the maximum tolerated dose (MTD) of ARGX-110 and/or the recommended Phase II dose (RP2D) in combination with a standard dose of azacytidine (AZA) in Phase 1; and to evaluate efficacy of…
- Trial name
- NCT03030612
- Testing
- ARGX-110, AZA
- Where
- 7 sites in France, Switzerland
- Volunteers
- 38 people
- Sponsor
- OncoVerity, Inc.
Degenerative Osteoarthritis, Rheumatoid Arthritis
All Polyethylene Tibia-VEGA Kiel
Obligatory Post-Marketing Clinical Follow-up (PMCF) as part of the post marketing surveillance plan for the product under investigation For this PMCF only CE-marked medical devices will be used within their intended purpose and…
- Conditions
- Degenerative Osteoarthritis, Rheumatoid Arthritis, Post-traumatic; Arthrosis, Other Instability, Knee
- Trial name
- APT-VEGA_KI (NCT02756702)
- Testing
- All-Poly
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Aesculap AG
Lymphoma
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of Tomivosertib (eFT-508).
- Trial name
- NCT02937675
- Testing
- Tomivosertib (eFT-508)
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Effector Therapeutics
Type 2 Diabetes Mellitus(T2DM)
A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
The primary objective of this study is to assess the pharmacokinetic parameters of saxagliptin and metformin in healthy male Chinese subjects.
- Trial name
- SAXA (NCT01755494)
- Testing
- Saxagliptin 5 mg, Metformin XR 500 mg, Mertformin XR 2 x 500 mg
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteer
A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam
In Part 1, the primary objective is to investigate the effect of multiple doses of itraconazole, an inhibitor of CYP3A4, on the pharmacokinetic (PK) profile of a single dose of ASTX660.
- Trial name
- NCT04411030
- Testing
- ASTX660, Midazolam, Itraconazole
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Astex Pharmaceuticals, Inc.
Kidney Transplantation
Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant Recipients
This study will assess safety and efficacy of AEB071 combined with everolimus in a CNI-free (calcineurin inhibitor) regimen in renal transplant recipients.
- Trial name
- AEB071 (NCT00504543)
- Testing
- AEB071, Certican, Neoral
- Where
- 26 sites in Argentina, Australia and 15 more
- Volunteers
- 311 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia
Real Life Assessment of Abilify Maintena
This is a non-interventional, Canadian, study in patients treated with Abilify Maintena™ for schizophrenia followed for 24 months, with 9 visits recommended.
- Trial name
- ReLiAM (NCT02131415)
- Where
- 17 sites in Canada
- Volunteers
- 200 people
- Sponsor
- Lundbeck Canada Inc.
Pharmacokinetics of ASP7657, Pharmacodynamics of ASP7657
A Study to Assess the Safety and Tolerability, Including Gastrointestinal Safety, Pharmacokinetics and Pharmacodynamics of ASP7657 in Caucasian Healthy Male and Female Subjects
The purpose of this study is to evaluate the safety and tolerability of single and multiple ascending oral doses of ASP7657 in healthy subjects.
- Conditions
- Pharmacokinetics of ASP7657, Pharmacodynamics of ASP7657, Healthy Subjects
- Trial name
- NCT02108548
- Testing
- ASP7657, naproxen
- Where
- United Kingdom
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Parenteral Nutrition Associated Liver Disease, Essential Fatty Acid Deficiency
Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis (PNAC)
This study will demonstrate Short-, mid-, and long-term safety in pediatric patients with Parenteral Nutrition-Associated Cholestasis treated with Omegaven®, which is indicated as a source of calories and fatty acids in this…
- Conditions
- Parenteral Nutrition Associated Liver Disease, Essential Fatty Acid Deficiency, Neurocognitive Deficit, Malnutrition
- Trial name
- NCT04807478
- Testing
- Omegaven® (fish oil triglycerides) Injectable Emulsion
- Sponsor
- Fresenius Kabi
Human Immunodeficiency Virus
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
The objective of this study is to observe and collect data on the usage, dosing, tolerability, and effectiveness of Kaletra (lopinavir/ritonavir) tablets in human immunodeficiency virus (HIV)-infected patients.
- Trial name
- NCT01097655
- Volunteers
- 3,049 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Multiple Myeloma
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
This study is a multi-cohort, open-label, multicenter Phase 2 study to evaluate the efficacy and safety of bb2121 in participants with relapsed and refractory multiple myeloma (RRMM) (Cohort 1), in participants with RRMM who…
- Trial name
- KarMMa-2 (NCT03601078)
- Testing
- bb2121, Lenalomide, Talquetamab
- Where
- 25 sites in United States, France and 4 more
- Volunteers
- 312 people
- Sponsor
- Celgene
COVID-19, Acute Respiratory Distress Syndrome
Tolerability and Efficacy of RJX in Patients With COVID-19
This study is designed as a 2-part, 2-cohort, double-blind, randomized, placebo controlled, multicenter Phase 1/2 study to evaluate the safety, tolerability and efficacy of RJX in patients with COVID-19.
- Conditions
- COVID-19, Acute Respiratory Distress Syndrome, SARS-CoV-2, Hypoxemia
- Trial name
- RJX (NCT04708340)
- Testing
- Rejuveinix (RJX) Active Comparator
- Where
- 3 sites in United States
- Volunteers
- 237 people
- Sponsor
- Reven Pharmaceuticals, Inc.
Cerebrotendinous Xanthomatoses
Safety and Efficacy of CDCA in CTX Chenodeoxycholic Acid (CDCA) in Patients Affected by Cerebrotendinous Xanthomatosis (CTX)
Retrospective study of CTX patients to investigate the safety and clinical efficacy of Chenodeoxycholic Acid
- Trial name
- NCT05499026
- Testing
- Chenodeoxycholic Acid
- Volunteers
- 28 people
- Sponsor
- Leadiant Biosciences Ltd.
Multiple Myeloma
Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma
The purpose of this study is to determine the safety and the maximum tolerated dose (MTD) of GRN163L when administered to patients with refractory or relapsed multiple myeloma.
- Trial name
- NCT00594126
- Testing
- Imetelstat Sodium (GRN163L)
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Geron Corporation
Atrial Fibrillation
Comparative Effectiveness of Oral Anticoagulants
This cohort study plans to identify initiators of oral anticoagulants using electronic claims data from a commercial insurance database to quantify associations between anticoagulant choice (warfarin and dabigatran) and the…
- Trial name
- NCT01847547
- Volunteers
- 5,982 people
- Sponsor
- Boehringer Ingelheim
ASTHMA
A Multicentre, Prospective, Non-interventional Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extra-fine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Outcomes
TriMaximize, a non-interventional trial aims to collect prospective, longitudinal data from asthma patients under routine care, for whom their treating physician has decided to prescribe Trimbow®…
- Trial name
- NCT05728749
- Testing
- Non-interventional
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Chiesi SAS
Hematological Malignancies, B-cell Non-Hodgkin Lymphoma
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
This clinical trial is designed to assess the safety, preliminary efficacy, and pharmacokinetics (PK) of DS3790a monotherapy and combination regimens in participants with hematological malignancies.
- Trial name
- NCT07220616
- Testing
- DS3790a, Combination drug
- Where
- 8 sites in United States, France and 2 more
- Volunteers
- 420 people
- Sponsor
- Daiichi Sankyo
Arthritis, Rheumatoid
Safety and Efficacy of Meloxicam Compared to Other Nonsteroidal Antiinflammatory Drugs (NSAIDs) in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, Neck, Shoulder and Arm Syndrome
Study to assess the safety profile of meloxicam by comparing incidence of gastrointestinal adverse events of meloxicam with that of NSAID in the routine daily therapeutic situation.
- Trial name
- NCT02180516
- Testing
- Meloxicam, Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac
- Volunteers
- 9,984 people
- Sponsor
- Boehringer Ingelheim
GIST
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of inlexisertib in combination with anticancer therapies.
- Trial name
- NCT05957367
- Testing
- Inlexisertib, Ripretinib
- Where
- 28 sites in United States, Denmark and 7 more
- Volunteers
- 94 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.